Image alt Bayer Logo Bayer Logo Bayer Logo Bayer Logo

nAMD Barometer Survey

What is the nAMD Barometer Survey?

The nAMD Barometer Leadership Coalition have designed a multi-country patient and clinician survey to investigate patients’ and clinical peers’ perspectives, as well as trends and practice patterns, relevant to the delivery of care for nAMD. The survey aims to:

  • Estimate global and country-specific levels of non-adherence to and non-persistence with anti-VEGF treatments for nAMD
  • Identify and assess barriers to adherence and persistence and drivers of non-adherence and non-persistence
  • Provide insights into patients’, physicians’ and allied healthcare professionals’ experiences of nAMD treatment
Survey icon

The survey will gather information from paper-based questionnaires distributed in clinics. The current planned recruitment for the survey is patients and HCPs from 20+ countries.

World map
Patients icon

The evidence base generated by the survey will be used to inform the development of meaningful interventions aimed at optimising care and ultimately improving long-term outcomes for patients

We will update you with the outcomes of this exciting initiative as soon as possible!

© 2019 Bayer AG

The nAMD Barometer Program is managed by clinical leaders in ophthalmology as well as representatives from the International Federation on Ageing (IFA), International Agency for Prevention of Blindness (IAPB) and Bayer.  

 

The activities of the nAMD Barometer Program are funded and facilitated by Bayer where the scientists and representatives from IFA and IAPB retain decision authority to the research scope, methods, analysis of findings and dissemination of the outputs of the nAMD Barometer Program. 

 

  • MA-PFM-OPHT-ALL-0308-1

Last update: 17/05/2021

Sponsored by

Image alt Image alt Image alt